Overview

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study will compare insulin lispro low mixture [LM] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with regard to the length of time that the overall blood sugar can be controlled. This study will also determine whether the safety of insulin lispro LM and any side effects that might be associated with it are different from those observed with insulin glargine, both in combination with the patient's oral diabetes medications. The addendum study (Intensification Addendum) will compare how different insulin treatments work to control blood sugar in patients whose diabetes could not be controlled by either insulin lispro LM or insulin glargine.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Biphasic Insulins
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc
Insulin, Isophane
Isophane insulin, insulin lispro drug combination 50:50